These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2068948)

  • 1. S-100 protein in ovarian tumors. A comparative immunohistochemical study of 135 cases.
    Lin M; Hanai J; Wada A; Ozaki M; Nasu K; Okamoto S; Matsumoto K
    Acta Pathol Jpn; 1991 Mar; 41(3):233-9. PubMed ID: 2068948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian tumors of low malignant potential (borderline tumors): immune morphology and current status.
    Neunteufel W; Gitsch G; Schieder K; Kölbl H; Breitenecker G
    Anticancer Res; 1989; 9(4):993-7. PubMed ID: 2684001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunohistochemical demonstration of CA 125, CA 19-9 and CEA in normal and pathologically changed adnexa].
    Neunteufel W; Breitenecker G
    Geburtshilfe Frauenheilkd; 1988 May; 48(5):334-7. PubMed ID: 3165079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
    Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M
    Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical factors and biomarkers in ovarian tumors development.
    Vrabie CD; Petrescu A; Waller M; Dina I
    Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic utility of WT1 immunostaining in ovarian sertoli cell tumor.
    Zhao C; Bratthauer GL; Barner R; Vang R
    Am J Surg Pathol; 2007 Sep; 31(9):1378-86. PubMed ID: 17721194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B7-H4 overexpression in ovarian tumors.
    Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
    Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.
    Ulbright TM
    Mod Pathol; 2005 Feb; 18 Suppl 2():S61-79. PubMed ID: 15761467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia.
    Kalir T; Wang BY; Goldfischer M; Haber RS; Reder I; Demopoulos R; Cohen CJ; Burstein DE
    Cancer; 2002 Feb; 94(4):1078-82. PubMed ID: 11920478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical evaluation of sialosyl-Tn antigens in various ovarian carcinomas.
    Ryuko K; Iwanari O; Kitao M; Moriwaki S
    Gynecol Oncol; 1993 May; 49(2):215-24. PubMed ID: 8504990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor markers in the human ovary and its neoplasms. A comparative immunohistochemical study.
    Nouwen EJ; Hendrix PG; Dauwe S; Eerdekens MW; De Broe ME
    Am J Pathol; 1987 Feb; 126(2):230-42. PubMed ID: 3548400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
    Vang R; Gown AM; Farinola M; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Judson K; Ronnett BM
    Am J Surg Pathol; 2007 May; 31(5):653-63. PubMed ID: 17460447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical characterization of ovarian borderline tumors of intestinal and mullerian types.
    Rutgers JL; Bell DA
    Mod Pathol; 1992 Jul; 5(4):367-71. PubMed ID: 1495942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human ovarian tumors express gamma-glutamyl transpeptidase.
    Hanigan MH; Frierson HF; Brown JE; Lovell MA; Taylor PT
    Cancer Res; 1994 Jan; 54(1):286-90. PubMed ID: 7903206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary.
    Esheba GE; Pate LL; Longacre TA
    Am J Surg Pathol; 2008 Apr; 32(4):600-7. PubMed ID: 18277882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
    Shibata K; Kajiyama H; Mizokami Y; Ino K; Nomura S; Mizutani S; Terauchi M; Kikkawa F
    Gynecol Oncol; 2005 Jul; 98(1):11-8. PubMed ID: 15907336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.
    Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M
    Int J Oncol; 2002 Aug; 21(2):315-20. PubMed ID: 12118327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
    Castellvi J; Garcia A; Rojo F; Ruiz-Marcellan C; Gil A; Baselga J; Ramon y Cajal S
    Cancer; 2006 Oct; 107(8):1801-11. PubMed ID: 16983702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.